Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Melinda Magyari, MD, PhD, consultant neurologist, the Danish Multiple Sclerosis Center, Copenhagen University Hospital, discusses the current body of data on treating pediatric multiple sclerosis (MS).
Transcript
How good is our current body of data on treating pediatric MS?
Because there have not been randomized control trials, only a few of them in pediatric-onset MS, the current evidence is not very strong. Randomized controlled trials exclude patients younger than 18 years. So I would, and as you can see in my presentation, most of the patients have been treated with intramuscular interferons. So the body of evidence on that treatment is rather good. But we need more observational data. We need large cohorts, maybe to merge them. Because the data is there, we just have to provide evidence.
Balancing Life and Myeloma: A Patient-Centered Approach
November 22nd 2024In this second part of our discussion with Don M. Benson, MD, PhD, from our recent Institute for Value-Based Medicine® event in Cleveland, Ohio, he explains how his ultimate goal for his patients is for them to live as long and as well as possible.
Read More